Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Sells $35,600.00 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Jack W. Callicutt sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $0.89, for a total transaction of $35,600.00. Following the completion of the transaction, the chief financial officer now owns 7,614 shares in the company, valued at approximately $6,776.46. This represents a 84.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Galectin Therapeutics Stock Up 32.2 %

GALT stock opened at $1.15 on Friday. The firm has a 50 day moving average of $2.34 and a two-hundred day moving average of $2.43. Galectin Therapeutics Inc. has a 12 month low of $0.73 and a 12 month high of $4.27. The company has a market capitalization of $72.18 million, a price-to-earnings ratio of -1.58 and a beta of 0.69.

Institutional Investors Weigh In On Galectin Therapeutics

Large investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in shares of Galectin Therapeutics in the second quarter worth about $43,000. JPMorgan Chase & Co. raised its stake in shares of Galectin Therapeutics by 161.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company’s stock valued at $84,000 after acquiring an additional 18,907 shares in the last quarter. Rhumbline Advisers acquired a new stake in Galectin Therapeutics in the 2nd quarter worth approximately $44,000. Geode Capital Management LLC boosted its position in Galectin Therapeutics by 2.5% during the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock worth $2,372,000 after purchasing an additional 20,817 shares during the period. Finally, State Street Corp grew its holdings in Galectin Therapeutics by 9.3% during the third quarter. State Street Corp now owns 251,014 shares of the company’s stock valued at $690,000 after purchasing an additional 21,399 shares during the last quarter. 11.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on GALT shares. StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. HC Wainwright reaffirmed a “neutral” rating on shares of Galectin Therapeutics in a research note on Friday.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.